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Abstract
Proliferation of glia and immune cells is a common pathological feature of many neurodegenerative diseases including
amyotrophic lateral sclerosis (ALS). Here, to investigate the role of proliferating cells in motor neuron disease, SOD1
G93A
transgenic mice were treated intracerebroventicularly (ICV) with the anti-mitotic drug cytosine arabinoside (Ara-C). ICV
delivery of Ara-C accelerated disease progression in SOD1
G93A mouse model of ALS. Ara-C treatment caused substantial
decreases in the number of microglia, NG2+ progenitors, Olig2+ cells and CD3+ T cells in the lumbar spinal cord of
symptomatic SOD1
G93A transgenic mice. Exacerbation of disease was also associated with significant alterations in the
expression inflammatory molecules IL-1b, IL-6, TGF-b and the growth factor IGF-1.
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Introduction
Amyotrophic lateral sclerosis is a fatal, adult-onset and rapidly
progressing neurodegenerative disorder characterized by the
selective degeneration of motor neuron in the brain and spinal
cord. Although the majority of ALS cases are sporadic,
approximately 10% of cases are familial and dominantly inherited.
Mutations in the gene encoding for the free radical-scavenging
metalloenzyme, copper/zinc superoxide dismutase (SOD1) is
causative in 20% of familial ALS cases [1]. Transgenic mice and
rats over-expressing various ALS-related SOD1 mutants develop
ALS-like phenotypes through a gain of unknown toxic properties
[2]. Various mechanisms have been proposed to explain mutant
SOD1 mediated motor neuron death in ALS including glutamate
induced excitotoxicity, oxidative damage, ER stress, mitochondrial
dysfunction, altered axonal transport and toxicity due to secreted
SOD1 [3]. Moreover, it has become apparent that mutant SOD1-
mediated toxicity does not occur solely within motor neurons
[1,4,5]. Many studies have now shown that expression of mutant
SOD1 in glial cells such as astrocytes and microglia causes intrinsic
damage, alterations in cell function and increased cytotoxic
potential of these cells which can result in enhanced damage to
neighboring motor neurons [6–11]. Accordingly, reducing expres-
sion of mutant SOD1 in either astrocytes or microglia significantly
delays disease progression and motor neuron death [4,12] which is
line with reports that wild-type microglia or astrocyte precursors
promote motor neuron survival and extends lifespan of rodent
models of ALS [13,14]. Other non-neuronal cells like T
lymphocytes can also confer neuroprotective inflammation in
mutant SOD1 mice [15,16].
To study the specific contribution of proliferating microglia to
motor neuron degeneration, we reported previously experimental
elimination of these cells by Ganciclovir treatment using doubly
transgenic mice SOD1
G93A; CD11b-TK [17]. Surprisingly, a 50%
reduction in reactive microglia had no effect of motor neuron
degeneration. Here, in order to achieve a more complete ablation
of proliferating cells in the CNS, we tested the effects of the anti-
mitotic drug cytosine arabinoside (Ara-C) in SOD1
G93A transgenic
mice when administered intracerebroventricularly (ICV). Ara-C
treatment caused efficient elimination of various proliferating cell
types but with a negative impact on disease progression.
Results
Reduction in microglia and T cell populations in Ara-C
treated SOD1
G93A mice
To determine the contribution of proliferating cells in motor
neuron degeneration in ALS, we administered ICV the anti-
mitotic drug Ara-C to SOD1
G93A transgenic mice. As proliferation
of glial cells can be observed pre-symptomatically in SOD1
G93A
transgenic mice [17], continuous ICV infusion of Ara-C was
initiated at 75 days of age (pre-symptomatic) for a duration of 42
days. Here, we show that microglia, T-cells as well as NG2+ and
Olig2+ cells were diminished by treatment with Ara-C (Figure 1).
Analysis at symptomatic stage of the disease (115 days)
demonstrated that treatment of SOD1
G93A transgenic mice with
Ara-C caused a significant 1.5 folds decrease in the number of
Iba1+ in the lumbar spinal cord of Ara-C treated animals
compared to vehicle treated controls (p=0.0086). Quantification
of CD68+ cells, a marker for activated and phagocytic microglia,
was also significantly reduced, suggesting that the ablation of
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it did not reach statistical significance, a trend for a reduced
number of NG2+ glial precursors was also seen (1.7 folds,
p=0.0713). Interestingly, a significant reduction in Olig2+ cells
was observed (2 folds, p=0236). No difference in the number of
GFAP+ astrocytes was found (p=0.3430). However, we found a
significant 3.8 folds decrease in the number of CD3+ T cells in
Ara-C treated mice compared to vehicle treated controls
(p=0.0122).
Reduced lifespan of Ara-C treated SOD1
G93A mice
Interestingly, SOD1
G93A transgenic mice (n=7) treated with
Ara-C had a mean survival of 134 days while vehicle treated
SOD1
G93A (n=9) had a mean survival of 141 days (p=0.0081)
(Figure 2). However, the decreased longevity of Ara-C treated
SOD1
G93A transgenic mice was not accompanied by an increased
degeneration of the motor neuron unit. Indeed, quantification of
Nissl stained motor neurons, L5 ventral root axons and
neuromuscular innervations of the gastrocnemius muscle in
symptomatic animals revealed no significant difference between
Ara-C and vehicle treated SOD1
G93A transgenic mice (Figure 3)
(motor neurons: p=0.9937; axons: p=0.1790; Denervated
synapses: p=0.8326, partially innervated synapses: p=0.9281,
innervated synapses: p=0.5504).
Inflammation was deregulated in Ara-C treated
transgenic mice
Real-time RT PCR analysis revealed that Ara-C induced
profound changes in SOD1
G93A the spinal cord of mice in levels of
inflammatory cytokines and growth factors (Figure 4). In Ara-C
Figure 1. Ara-C treatment caused a decrease in microglia, NG2+ progenitors, oligodendrocytes, astrocytes and T cells in the spinal
cord of SOD1
G93A mice. Immunofluorescence for cell markers Iba1 (A), CD68 (B), NG2 (C), GFAP (D), CD3 (E) and Olig2 (F) in the lumbar spinal cord
of mutant SOD1 transgenic mice treated with vehicle or Ara-C. (G) Quantification of Iba positive cells showed a 1.5 folds reduction of cells in Ara-C
treated mice compared to controls (**p=0.0086). (H) Quantification of CD68 marker showed a 1.5 folds reduction of cells in Ara-C treated mice
compared to controls (**p=0.0099). (I) Quantification of NG2+ marker showed a 1.7 folds reduction of cells in Ara-C treated mice compared to
controls (p=0.0713) (J) Quantification of GFAP marked cells showed a slightly reduced number of astrocytes (1.2 folds) in Ara-C treated mice
compared to controls, although this result was not significant (p=0.3430). (K) Quantification of Olig2 positive cells showed a 2.0 folds reduction of
cells in Ara-C treated mice compared to controls (*p=0.0236) (L) Quantification of CD3+ cells showed 3.8 folds reduction of cells in Ara-C treated mice
compared to controls (*p=0.0122). All mice were analyzed at 115 days. All values are means 6 SEM. Scale bars: 100 mm.
doi:10.1371/journal.pone.0034932.g001
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folds (p=0.0072) compared to vehicle treated animals, which is in
line with the microglia depletion. Unexpectedly, no significant
changes were seen in TNF-a and IL-4 levels. In contrast, IL-6
mRNA in Ara-C treated mice was upregulated by 1.6 folds
(p=0.0014) whereas the growth factors TGF-b1 and IGF-1 were
greatly diminished, by 1.47 (p=0.0148) and 2.42 (p=0.0108) folds
respectively.
Discussion
Motor neuron disease in mutant SOD1-mediated ALS is a non-
cell autonomous process [1,18]. In this study, we have shown that
the depletion of proliferating cells in the CNS of SOD1
G93A mice,
consisting mainly of NG2+ and Olig2+ cells as well as microglia
and T-cells, caused a significant reduction in lifespan. Surprisingly,
this decrease in survival of transgenic mice treated with Ara-C was
not correlated with a reduction in motor neuron survival, axonal
degeneration or muscle innervation at the symptomatic phase of
disease. Similarly, we have previously observed that the specific
and substantial ablation of proliferating microglia had no effect on
motor neuron degeneration in mutant SOD1 mice [17]. As the
assessment of motor unit degeneration was performed at the
symptomatic stage of disease (115d), it is possible that the increased
motor neuron degeneration that likely precipitated a reduction in
survival occurred a later time in our study.
The role of oligodendrocytes in the pathology of ALS has not
been extensively studied [38]. However, a study has suggested that
mutant SOD1 expressing oligodendrocytes may not significantly
contribute to the disease process [39]. Oligodendrocyte precursor
cells express the chondroitin sulfate proteoglycan NG2, although
NG2+ cells have been found to significantly proliferate in ALS we
did not find a significant decrease in these cells following Ara-C
treatment [17,35]. However, it is interesting to note that a 2 fold
reduction in the number of cells expressing the transcription factor
Olig2 was observed. Although Olig2-positive progenitors in the
embryonic spinal cord give rise can give rise to oligodendrocytes,
motor neurons subset of astrocytes and ependymal cells, a
considerable number of mature oligodendrocytes have been
shown to be immunoreactive for Olig2 in the adult brain
[36,37]. Further study of the role of oligodendrocytes in the
pathology of ALS is warranted.
In vitro and in vivo studies have shown that activated microglia
can cause the degeneration of motor neurons [10,19–21].
Moreover, microglia expressing mutant SOD1 have increased
cytotoxic potential when compared to wild-type microglia [7,11].
If it is correct that microglia participate in the degenerative process
in ALS, why did microglia elimination by Ara-C treatment was
associated with a decrease in the survival of SOD1
G93A transgenic
mice? This may reflect the ambivalent potential of microglial cells
that can be differentially activated to exhibit either neuroprotec-
tive or neurotoxic phenotypes [22]. Neurotoxic microglia express
inflammatory molecules such as IL-1b, TNF-a, are a potent
source of reactive oxygen species and are sometimes termed M1
microglia. On the other hand, neuroprotective microglia are
characterized by the expression of anti-inflammatory cytokines
and neurotrophic factors such as IGF-1. Interestingly, microglia
showing a M1 neurotoxic phenotype have shown to be mostly
present at the end-stages of the disease in mutant SOD1
G93A mice
whereas the neuroprotective M2 microglia phenotype is predom-
inantly present at the early stages of the disease [22]. In this
experiment, we treated the mice at a pre-symptomatic phase of
disease (75 days), a stage where the neuroprotective microglial
phenotype is predominant. We may therefore have eliminated the
‘‘good’’ microglia, causing an adverse effect.
Treatment with Ara-C also resulted in a significant decrease in
the number of CD3+ T cells in the CNS of mutant SOD1
G93A
transgenic mice. However, whether this reduction is a direct or
indirect consequence of Ara-C treatment remains unclear.
Interestingly, a number of studies have shown the importance of
T cells in delaying motor neuron degeneration in ALS [15,16,23].
However, this has been recently challenged by Tada and collegues
[24]. As exacerbation of disease is paralleled with a 3.76 folds
Figure 2. Ablation of proliferating cells in CNS decreases lifespan of SOD1
G93A mice. Kaplan-Meier survival curve shows that transgenic
mice Sod1
G93A (n=7) treated with Ara-C between 75 and 115 days had a mean survival of 134 days while untreated SOD1
G93A (n=9) had a mean
survival of 141 days. Log-rank test shows that this difference is significant (p=0.0081).
doi:10.1371/journal.pone.0034932.g002
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cells in SOD1 mediated ALS.
Not surprisingly, reducing the number of proliferating cells
within the CNS resulted in the modulation of the inflammatory
response in SOD1
G93A mice. However, we cannot conclude that
inflammation was increased or reduced. Some pro-inflammatory
cytokines were upregulated (IL-6) as well as down-regulated (IL-
1b), whereas anti-inflammatory cytokines were downregulated
(TGF-b1) or upregulated (IL-6). Nevertheless, a decrease in the
expression of TGF-b1 and IGF-1 may have contributed to the
exacerbation of disease. TGF-b is a pleitropic cytokine which
regulates a wide range of cellular responses [25]. TGF-b can
reduce the production of reactive oxygen species by activated
microglia and promotes an M2 microglial phenotype. Interesting-
ly, some evidence also demonstrates that TGF-b signalling can
protect neurons from glutamate-mediated excitotoxicity. More-
over, the administration of TGF-b causes the transient improve-
ment in the phenotypes of SOD1
G93A transgenic mice [26]. IGF-1
is another potent trophic factor produced, in part, by microglia in
the CNS of SOD1 transgenic mice and has been shown to delay
motor neuron degeneration in several studies using SOD1
transgenic mice or other models of motor neuron degeneration
[27–34].
Studies investigating the role of microglial cells and inflamma-
tion in mutant SOD1 animal models have yielded confounding
results. Numerous signals can influence microglial cell phenotypes
and the immune responses throughout the course of the disease
enabling an exacerbation of damage or protection of motor
neurons. Drugs, genetic manipulation, cell transplantation or any
other treatment will undoubtedly cause alterations in many
signalling pathways. In depth rather and then superficial analysis
of glial cell behaviour should be performed in order to reach
appropriate conclusions regarding the beneficial or detrimental
role of these cells in mutant SOD1-mediated ALS. For instance,
the upregulation of the integrin CD11b by microglial cells is often
associated with increased activation and detrimental function of
microglia. Yet, in a study by Chiu and colleagues [16], a reduction
in CD11b immunoreactivity by microglia in mutant SOD1 mice
correlated with a decrease in IGF-1 production and in
neurotrophic potential of these cells. Here, the substantial
reduction in the number of microglia and T cells in the CNS of
SOD1
G93A transgenic mice by Ara-C treatment had no effect on
motor neuron survival but it significantly reduced lifespan. This





G93A transgenic mice [stock number 002726] were
acquired from The Jackson Laboratory (Bar Harbor, ME). Mice
were genotyped in accordance with Jackson Laboratory protocols.
The use and maintenance of the mice described in this article were
performed in accordance to the Guide of Care and Use of Experimental
Animals of the Canadian Council on Animal Care (Approval number is
2011137-1).
Figure 3. Motoneuron degeneration of SOD1
G93A mice was not affected by Ara-C treatment. (A) Axons in the ventral root of transgenic
mice treated or with Ara-C or vehicle. Quantification of the total number of axons showed no difference between both groups (p=0.1790). (B) Nissl
stain for neuronal cells. Quantification of motoneurons showed no difference between both groups (p=0.9937). (C) Immunofluorecence for
innervation of muscle fibres in the gastrocnemius muscle. Number of innervated, partially innervated and denervated fibre in Ara-C treated mice did
not differ from vehicle-treated controls (Denervated: p=0.8326, partially innervated: p=0.9281, innervated: p=0.5504). (A–B) Mice were analyzed at
115 days and (C) end-stage (6140 days). All values are means 6 SEM. Scale bars: (A) 100 mm and (B–C) 50 mm.
doi:10.1371/journal.pone.0034932.g003
Figure 4. Modulation of the inflammatory response in Ara-C treated SOD1
G93A mice. Quantitative RT-PCR results (values are normalized to
GADPH and relative to wild-type control treated with vehicle; no significant difference was found between wild-type controls treated with vehicle or
M-CSF for any marker). Significant differences were found between Ara-C and vehicle treated SOD1
G93A in levels of mRNA for TGF-b1 (*p=0.0148), IL-
1b (**p=0.0072), IL-6 (**p=0.0014) and IGF-1 (*p=0.0108). Note that all mRNA levels were significantly higher in vehicle treated transgenic mice
compared to WT, treated or not (p,0.0025), except for IL-4 (p=0.7582). All values are mean 6 SEM; n(WT)=9, n(Tg-Vehicle)=6, n(Tg-Ara-C)=15.
doi:10.1371/journal.pone.0034932.g004
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For intracerebroventricular delivery of Ara-C (10 mg/ml,
Cytarabine; Roche) or vehicle, mice at 75 d of age were
anesthetized with isoflurane and were placed in a stereotaxic
apparatus (David Kopf Instruments, Tujunga, CA). The right
lateral ventricule was then reached (21.75 mm lateral, +1.00 mm
antero-posterior and 22.0 mm dorsoventral to the bregma) with a
33-gauge stainless steel cannula (Plastics One, Roanoke, VA) that
was connected to an Alzet osmotic mini-pump model 2004
(Durect, Cupertino, CA).
Tissue collection for immunohistochemical analyses
At 115 days of age, following 42 days of ICV infusion of ARA-C
or vehicle, mice were anesthetized and transcardially perfused with
NaCl 0.9% and fixed with 4% paraformaldehyde. Another group
of mice were sacrificed at end-point to assess survival but tissues
were not used for analysis. Dissected spinal cord and muscle tissues
were postfixed for 24 h in 4% paraformaldehyde and equilibrated
in a solution of PBS-sucrose (20%) for 48 h. Spinal cord tissues
were cut in 25 mm thick sections with a Leica frozen microtome
and kept in a cryoprotective solution at 220uC. Gastrocnemius
muscles were cut in 40 mm thick cryostat sections. Dissected dorsal
root ganglia (DRG) were postfixed in a solution of 3%
glutaraldehyde for a period of 48 h, washed in PBS, treated with
1% osmium tetroxide for 2 h, and dehydrated through graded
alcohol solutions. Prior to Epon plastic embedding, DRG were
further dissected to ensure that all ventral root axons would be
sampled at a distance of 3 mm from the DRG cell body. Semithin
cross-sections (1 mm) were stained with toluidine blue, rinsed, and
coverslipped.
Immunohistochemistry
Spinal cord sections were stained with the following antibodies:
anti-CD68 (Serotec), anti-NG2 (Millipore), anti-GFAP (Dako or
Millipore), anti-Iba1 (Wako) and anti-CD3 (BD Pharmingen)
according to standard techniques. For light microscopy, sections
were developed with Vectastain ABC kit, reacted with nickel-
diaminobenzidine (Vector Laboratories). For immunofluores-
cence, sections were stained with the fluorophore-coupled
secondary antibody Alexa-488, or Alexa 594 (Invitrogen) and
counterstained with DAPI.
Quantitative analyses
Every 12th section of spinal cord was immunostained for
selected cellular subtype (microglia, astrocyte, glial precursors or T
cells) or Nissl stained to identify motor neurons in the lumbar
spinal cord. The density of labeled cells was estimated by the
optical fractionator method using Stereo Investigator software
(MBF Biosciences, Williston, USA) For an Iba1, CD68, GFAP,
CD3, Olig2 or NG2-positive cells to be counted; a distinct cell
body and visible DAPI marked nucleus had to be within the
optical dissector height. The counting parameters were the
distance between counting frames (400 mm), the counting frame
size (100 mm6100 mm), the dissector height (13 mm) and the guard
zone thickness (1 mm). Motor neurons were identified on the basis
of their correct anatomical location (ventral horn/laminae 9),
required a distinct nucleolus within the plane of the optical
dissector and had a cross sectional area $250 mm
2. Counting
parameters were identical to immunostained sections except for
the distance between counting frames (150 mm). Bilateral L5
ventral root axons were counted at a magnification of 606using
Stereo Investigator software and interior of axons were marked in
each frame until the entire ventral root section had been sampled.
Counts represent the mean axonal count for the left and right
ventral roots. Bilateral gastrocnemius muscles were sampled and
stained by immunofluorescence with rhodamine bungarotoxin
(Invitrogen), anti-NFM (MAB5254, Millipore) and a mix of SV2
(DSHB, University of Iowa, Iowa, IA, USA) and synaptophysin
(DAKO) antibodies. End-plates were scored as innervated if there
was complete overlap with axon terminal, or denervated if the
end-plate was not associated with an axon. Partial overlap or
association with preterminal axon only was scored as intermediate
innervation. Every fourth section was systematically sampled in
order to evaluate all neuromuscular junctions present.
Quantitative RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen)
according to the manufacturer’s instructions and then digested
with deoxyribonuclease to remove any contaminating genomic
DNA (Turbo DNA-free from Ambion, Austin, TX). RNA
quantity and quality was assessed using an Agilent Technologies
2100 bioanalyzer and RNA 6000 Nano LabChip kit (Agilent, CA,
USA). Complementary DNA (cDNA) was generated from
5625 ng of total RNA using a random primer hexamer following
the protocol for Superscript II (Invitrogen). Equal amounts of
cDNA (100 ng) were run in triplicate and amplified in a 15-ml
reaction containing 7.5 mLo f2 6 Universal PCR Master Mix
(Applied Biosystems, CA, USA), 10 nM of Z-tailed forward
primer, 100 nM of reverse primer, 250 nM of Amplifluor
Uniprimer probe (Millipore), and 1 mL of cDNA target. Moreover,
no-template controls were used as recommended. The mixture
was incubated at 50uC for 2 min, at 95uC for 4 min, and then
cycled at 95uC for 15 s and at 55uC for 30 s 55 times using the
Applied Biosystems Prism 7900 Sequence Detector. Amplification
efficiencies were validated and normalized to GADPH gene and
quantities of target gene were calculated according to a standard
curve. Primers were designed using Primer Express 2.0 (Applied
Biosystems). Amplicons were detected using the Amplifuor
UniPrimer system were all forward primers used contained a 59
Z sequence: ACTGAACCTGACCGTACA.
Statistical analyses
Data were analyzed using Prism 5.0 software (Graphpad
software, CA, USA). Quantification data were computed by
performing two-tailed Student’s t test and survival data using
Mantel-Cox log-rank tests. Welch’s correction was used when
variances between samples were statistically different (determined
using Fisher’s test to compare variances). Data are expressed as
mean 6 SEM; p,0.05 was considered statistically significant.
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